No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ITCI240517C90000
- 0.05
- 0.000.00%
15min DelayClose May 16 13:22 ET
0.00High0.00Low
0.05Open0.05Pre Close0 Volume1.68K Open Interest90.00Strike Price0.00Turnover237.58%IV35.35%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type0.0161Delta0.0044Gamma1330.60Leverage Ratio-0.0500Theta0.0000Rho21.39Eff Leverage0.0015Vega
Intraday
- 5D
- 1D
News
This Intra-Cellular Therapies Insider Reduced Their Stake By 34%
Viewing insider transactions for Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI ) over the last year, we see that insiders were net sellers.
Buy Rating Affirmed on Intra-Cellular Therapies Amid Strong Sales and Promising Clinical Trials
Analyst Ratings For Intra-Cellular Therapies
Throughout the last three months, 18 analysts have evaluated Intra-Cellular Therapies (NASDAQ:ITCI), offering a diverse set of opinions from bullish to bearish.The following table provides a quick ove
Intra-Cellular Therapies to Participate in Two Upcoming Investor Conferences
Intra-Cellular Therapies: A Strong Buy on Robust Financials and Promising Caplyta Prospects
RBC Capital Remains a Buy on Intra-Cellular Therapies (ITCI)
Comments
🎯 Ph 3 readouts in Q2 2024...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
$Intra-Cellular Therapies(ITCI.US$ Phase 3
$CG Oncology(CGON.US$ Phase 3
$Hutchmed (China)(HCM.US$ Phase 3
$Viracta Therapeutics(VIRX.US$ Phase 3
$GlycoMimetics(GLYC.US$ Phase 3
$Annexon(ANNX.US$ Phase 3
$Lipocine(LPCN.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$UroGen Pharma Ltd(URGN.US$ Phase 3
$Lyra Therapeutics(LYRA.US$ Phase 3
$Citius Pharmaceuticals(CTXR.US$ Phase 3
$Marinus Pharmaceuticals(MRNS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3...
15
Intra-Cellular Therapies is nearing breakeven, contingent on maintaining a 57% annual growth rate. Its lack of debt, unusual for a pharma company, reduces investment risk.
2
🎯 Ph 3 readouts in Q1 2024...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
$Pfizer(PFE.US$ Phase 3
$Palatin Technologies(PTN.US$ Phase 3
$Annovis Bio(ANVS.US$ Phase 3
$BioCardia(BCDA.US$ Phase 3
$Atea Pharmaceuticals(AVIR.US$ Phase 3
$Ironwood Pharmaceuticals(IRWD.US$ Phase 3
$Alnylam Pharmaceuticals(ALNY.US$ Phase 3
$Axsome Therapeutics(AXSM.US$ Phase 3
$ $Novocure(NVCR.US$ Phase 3
$ROCHE HOLDING AG(RHHBY.US$ Phase 3
$FibroGen(FGEN.US$ Phase 3
$ACADIA Pharmaceuticals(ACAD.US$ Phase 3
$Sellas Life Sciences(SLS.US$...
16
The market seems optimistic about Intra-Cellular Therapies, Inc. given its strong revenue growth and share price momentum. It's recommended to take a closer look at this stock.
Read more